Family Asset Management LLC Has $366,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Family Asset Management LLC cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,502 shares of the medical instruments supplier’s stock after selling 155 shares during the period. Family Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $366,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Everhart Financial Group Inc. bought a new position in Becton, Dickinson and Company during the 3rd quarter worth approximately $234,000. Verdence Capital Advisors LLC raised its holdings in Becton, Dickinson and Company by 5.7% in the third quarter. Verdence Capital Advisors LLC now owns 1,411 shares of the medical instruments supplier’s stock worth $365,000 after purchasing an additional 76 shares during the period. WESPAC Advisors LLC acquired a new stake in Becton, Dickinson and Company in the third quarter worth $624,000. IFM Investors Pty Ltd boosted its position in shares of Becton, Dickinson and Company by 3.5% during the third quarter. IFM Investors Pty Ltd now owns 55,888 shares of the medical instruments supplier’s stock worth $14,449,000 after purchasing an additional 1,890 shares in the last quarter. Finally, Hills Bank & Trust Co grew its holdings in shares of Becton, Dickinson and Company by 6.7% in the 3rd quarter. Hills Bank & Trust Co now owns 7,004 shares of the medical instruments supplier’s stock valued at $1,811,000 after buying an additional 441 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.8 %

Shares of Becton, Dickinson and Company stock traded up $1.92 on Monday, hitting $236.60. The company had a trading volume of 1,255,426 shares, compared to its average volume of 1,412,024. The stock has a 50-day moving average of $238.35 and a 200-day moving average of $240.12. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The firm has a market capitalization of $68.38 billion, a P/E ratio of 52.11, a P/E/G ratio of 1.92 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.86 EPS. Research analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Analyst Ratings Changes

Separately, Barclays raised their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $281.40.

Insider Buying and Selling

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.